Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 6Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Patients With Any Advanced Solid Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Genital Neoplasms, Female 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Cisplatin 7Oxaliplatin 5Paclitaxel 4Fluorouracil 4Carboplatin 4Albumin-Bound Paclitaxel 4Taxes 3Mitomycin 3130-nm albumin-bound paclitaxel 3Nivolumab 2Leucovorin 2Doxorubicin 2veliparib 1tremelimumab 1talimogene laherparepvec 1soluble LAG-3 protein, human 1sodium thiosulfate 1pembrolizumab 1nintedanib 1irinotecan sucrosofate 1durvalumab 1dehydroftorafur 1cc-486 1avelumab 1Trastuzumab 1Semaxinib 1Radiotherapy 1Radiation 1Platinum 1Pharmacogenomic Variants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Peritoneal Neoplasms × nintedanib × Clear all
NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Boehringer Ingelheim

Phase 1 Completed
19 enrolled 21 charts
Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡